{"prompt": "['2017N330177_04', 'CONFIDENTIAL', '205678', 'As part of an ocular sub-study, approximately 30 participants (~15 per dose level) will', 'be evaluated to study the effect of ophthalmic topical corticosteroids on', 'GSK2857916-associated corneal findings and to further characterize these findings.', 'Number of Participants: The sample size calculation was performed using East 6.4', 'software as a starting point, based on the ORR comparison between the GSK2857916', 'arm and the historical control. Based on the simulation results with the planned sample', 'size of 65 participants there is 86.90% power to reject the null hypothesis within each', 'arm with a 1-sided type I error of 1.23%.', 'Approximately 170 participants were initially planned to be screened to enroll a', 'minimum of 155 participants at approximately 60 investigational sites globally. A', 'minimum of 130 participants (65/arm) were planned to be enrolled to 2 arms receiving', 'frozen liquid solution of GSK2857916, which includes ~30 participants from the ocular', 'sub-study. Approximately 200 participants will be enrolled onto the frozen liquid portion', 'of the study.', 'Approximately, twenty-five additional participants will be enrolled into the independent', 'lyophilized drug product cohort.', 'Treatment Groups and Duration: In this two-arm randomized study, GSK2857916 will', 'be administered at 2 dose levels (2.5 mg/kg or 3.4 mg/kg) to participants by IV infusion', 'on the Q3W schedule at the study site. The dose will be based on actual body weight', 'calculated at baseline and may be reduced to address toxicities according to protocol', 'guidelines.', 'GSK2857916 will be administered on Day 1 of each cycle. Premedication is not required', 'unless deemed medically necessary by the investigator, in which case it should be', 'administered according to institutional recommendations. If an infusion-related reaction', '(IRR) occurs during administration, the infusion rate may be reduced or halted at the', 'discretion of the investigator depending on the severity of the symptoms.', 'Participants will be treated until disease progression or until unacceptable toxicity.', 'Inclusion Criteria: Participants are eligible to be included in the study only if all the', 'following criteria apply:', '1. Provide signed written informed consent, which includes compliance with the', 'requirements and restrictions listed in the consent form', '2.', 'Male or female, 18 years or older (at the time consent is obtained)', '3.', 'Eastern Cooperative Oncology Group (ECOG) performance status of 0-2', '4. Histologically or cytologically confirmed diagnosis of MM as defined in IMWG,', '2014 criteria, and', 'a. Has undergone stem cell transplant or is considered transplant ineligible, and', 'b. Has failed at least 3 prior lines of anti-myeloma treatments, including an anti-', 'CD38 antibody (e.g., daratumumab) alone or in combination, and is refractory', '15']['2017N330177_04', 'CONFIDENTIAL', '205678', 'to an IMiD (i.e., lenalidomide or pomalidomide), and to a proteasome', 'inhibitor (e.g., bortezomib, ixazomib or carfilzomib).', 'Refractory myeloma is defined as disease that is nonresponsive while on', 'primary or salvage therapy, or progresses within 60 days of last therapy.', 'Nonresponsive disease is defined as either failure to achieve at least minimal', 'response or development of progressive disease (PD) while on therapy.', '5.', 'Has measurable disease with at least one of the following:', 'a.', 'Serum M-protein >0.5 g/dL (>5 g/L)', 'b. Urine M-protein >200 mg/24h', 'c. Serum FLC assay: Involved FLC level >10 mg/dL (100 mg/L) and an', 'abnormal serum free light chain ratio (<0.26 or >1.65)', '6. Participants with a history of autologous stem cell transplant are eligible for study', 'participation provided the following eligibility criteria are met:', 'a.', 'transplant was > >100 days prior to study enrolment', 'b. no active infection(s)', 'c. participant meets the remainder of the eligibility criteria outlined in this', 'protocol', '7.', 'Adequate organ system function.', '8.', 'Female Participants: Contraceptive use by men or women should be consistent with', 'local regulations regarding the methods of contraception for those participating in', 'clinical studies.', 'A female participant is eligible to participate if she is not pregnant or breastfeeding,', 'and at least one of the following conditions applies:', 'Is not a woman of childbearing potential (WOCBP)', 'OR', 'Is a WOCBP and using a contraceptive method that is highly effective (with a', 'failure rate of <1% per year), preferably with low user dependency, during the', 'intervention period and for at least 80 days after the last dose of study', 'intervention and agrees not to donate eggs (ova, oocytes) for the purpose of', 'reproduction during this period. The investigator should evaluate the', 'effectiveness of the contraceptive method in relationship to the first dose of', 'study intervention.', 'A WOCBP must have a negative highly sensitive serum pregnancy test (as', 'required by local regulations) within 72 hours before the first dose of study', 'intervention.', 'The investigator is responsible for review of medical history, menstrual history,', 'and recent sexual activity to decrease the risk for inclusion of a woman with an', 'early undetected pregnancy.', '16']\n\n###\n\n", "completion": "END"}